Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSS1 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
DSS1 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of the DSS1 (deleted in split-hand/split-foot malformation 1, also known as SEM1) gene. DSS1 is a highly conserved protein that plays critical roles in stabilizing BRCA2, regulating homologous recombination, and maintaining RNA-mediated genomic stability as a member of the TREX2 complex. In preclinical research, DSS1 siRNA is utilized as a laboratory tool to investigate the functional role of DSS1 in cancer cell proliferation, DNA damage repair, and chemosensitivity. Knockdown of DSS1 via siRNA has been shown to highly sensitize breast cancer cells to DNA-damaging chemotherapeutic agents (such as doxorubicin, paclitaxel, camptothecin, and etoposide) in a BRCA2-independent manner, highlighting DSS1 as a potential therapeutic target for overcoming drug resistance.
- Other names
- DSS1 small interfering RNADSS-1 small interfering RNADSS 1 small interfering RNAsiDSS1siDSS-1siDSS 1
02
Targets
26S proteasome
Beyond the preview
Go deeper on DSS1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSS1 siRNA.